[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA:A Cancer Journal for Clinicians, 2018, 68(6):394-424.
[2] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2019[J]. CA:A Cancer Journal for Clinicians, 2019, 69(1):7-34.
[3] 陈万青, 孙可欣, 郑荣寿, 等. 2014年中国分地区恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2018, 27(1):1-14. Chen Wanqing, Sun Kexin, Zheng Rongshou, et al. Report of cancer incidence and mortality in different areas of China, 2014[J]. China Cancer, 2018, 27(1):1-14
[4] 吕关平, 陈磊, 沈珍瑶. 基于文献计量学的长江三峡水库研究进展[J]. 科技导报, 2015, 33(9):108-119. Lü Guanping, Chen Lei, Shen Zhenyao. Progress on three gorges reservoir research:From a bibliometrics perspective[J]. Science & Technology Review, 2015, 33(9):108-119.
[5] Ren Y G, Wang Q J, Tian L, et al. Bibliometric analysis on lung cancer in China during the period of 2001-2010[J]. Thoracic Cancer, 2012, 3(4):363-366.
[6] Ho Y S, Satoh H, Lin S Y. Japanese lung cancer research trends and performance in Science Citation Index[J]. Internal Medicine, 2010, 49(20):2219-2228.
[7] Ho Y S, Nakazawa K, Sato S, et al. Cisplatin for small cell lung cancer:Associated publications in Science Citation Index Expanded[J]. Oncology Letters, 2013, 5(2):684-688.
[8] 丁宁. 我国肺癌相关研究现状与热点的文献计量分析[J]. 中华医学图书情报杂志, 2014, 23(4):67-72. Ding Ning. Status quo and hot spots of lung cancer-related studies in China:A bibliometric analysis[J]. Chinese Journal of Medical Library and Information Science, 2014, 23(4):67-72.
[9] He X R, Han S Y, Li P P. Recent highlights of Chinese medicine for advanced lung cancer[J]. Chinese Journal of Integrative Medicine, 2017, 23(5):323-330.
[10] 李艳, 陆晴, 李雅梅. 肺癌症状群研究英文文献计量分析[J]. 护理学杂志, 2018, 33(9):92-97. Li Yan, Lu Qing, Li Yamei. Bibliometric analysis of English written articles regarding symptom clusters in lung cancer patients[J]. Journal of Nursing Science, 2018, 33(9):92-97.
[11] 刘彬, 陈柳, 袁佩佩. 国家自然科学基金资助的2009-2013年SCI收录文献计量分析[J]. 中国科学基金, 2014, 28(3):214-218. Liu Bin, Chen Liu, Yuan Peipei. Bibliometric analysis on SCI covered papers funded by NSFC from 2009 to 2013[J]. Bulletin of National Natural Science Foundation of China, 2014, 28(3):214-218.
[12] 刘彬, 邓秀新. 基于文献计量的园艺学基础研究发展状况分析[J]. 中国农业科学, 2015, 48(17):3504-3514. Liu Bin, Deng Xiuxin. Basic research development status of horticulture based on bibliometric analysis[J]. Scientia Agricultura Sinica, 2015, 48(17):3504-3514.
[13] 叶鹰. H指数和类H指数的机理分析与实证研究导引[J]. 大学图书馆学报, 2007, 25(5):2-5. Ye Ying. An introduction to mechanic analysis and positive researches of H-index and H-like indexes[J]. Journal of Academic Libraries, 2007, 25(5):2-5.
[14] Van-Haselen R. The h-index:A new way of assessing the scientific impact of individual CAM authors[J]. Complementary Therapies in Medicine, 2007, 15(4):225-227.
[15] 孙颉. 基于文献计量的国内外柿研究现状分析[J]. 果树学报, 2017, 34(6):706-714. Sun Jie. Current situation of persimmon science and technology in the world based on bibliometrics analysis[J]. Journal of Fruit Science, 2017, 34(6):706-714.
[16] 李小涛. ESI高被引论文视角下图情学科的发展与创新[J]. 中华医学图书情报杂志, 2016, 25(10):52-58. Li Xiaotao. Development and innovation in library and information science in view of ESI-based highly cited papers[J]. Chinese Journal of Medical Library and Information Science, 2016, 25(10):52-58.
[17] 陈楠楠, 李娟, 魏青山. ESI高被引论文收录和引证分析探索[J]. 情报探索, 2018, 12:39-43. Chen Nannan, Li Juan, Wei Qingshan. Exploration on the collection and citation analysis of ESI highly citied papers[J]. Information Research, 2018, 12:39-43.
[18] Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA:A Cancer Journal for Clinicians, 2011, 61(2):69-90.
[19] Torre L A, Bray F, Siegel R L, et al. Global cancer statistics, 2012[J]. CA:A Cancer Journal for Clinicians, 2015, 65(2):87-108.
[20] Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide:Sources, methods and major patterns in Globocan 2012[J]. International Journal of Cancer, 2015, 136(5):E359-E386.
[21] Ferlay J, Shin H R, Bray F, et al. Estimates of worldwide burden of cancer in 2008:Globocan 2008[J]. International Journal of Cancer, 2010, 127(12):2893-2917.
[22] Siegel R, Naishadham D, Jemal A, et al. Cancer statistics, 2012[J]. CA:A Cancer Journal for Clinicians, 2012, 62(1):10-29.
[23] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2016[J]. CA:A Cancer Journal for Clinicians, 2016, 66(1):7-30.
[24] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013[J]. CA:A Cancer Journal for Clinicians, 2013, 63(1):11-30.
[25] Siegel R, Ma J M, Zou Z H, et al. Cancer statistics, 2014[J]. CA:A Cancer Journal for Clinicians, 2014, 64(1):9-29.
[26] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2015[J]. CA:A Cancer Journal for Clinicians, 2015, 65(1):5-29.
[27] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2017[J]. CA:A Cancer Journal for Clinicians, 2017, 67(1):7-30.
[28] Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010:A systematic analysis for the global burden of disease study 2010[J]. Lancet, 2012, 380(9859):2095-2128.
[29] Topalian S L, Hodi F S, Brahmer J R, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. New England Journal of Medicine, 2012, 366(26):2443-2454.
[30] Lim S S, Vos T, Flaxman A D, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010:A systematic analysis for the global burden of disease study 2010[J]. Lancet, 2012, 380(9859):2224-2260.
[31] Chen W Q, Zheng R S, Baade P D, et al. Cancer statistics in China, 2015[J]. CA:A Cancer Journal for Clinicians, 2016, 66(2):115-132.
[32] Mok T S, Wu Y L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J]. New England Journal of Medicine, 2009, 361(10):947-957.
[33] Gerlinger M, Rowan A J, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing[J]. New England Journal of Medicine, 2012, 366(10):883-892.
[34] Brahmer J R, Tykodi S S, Chow L Q M, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. New England Journal of Medicine, 2012, 366(26):2455-2465.
[35] Aberle D R, Adams A M, Berg C D, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening[J]. New England Journal of Medicine, 2011, 365(5):395-409.
[36] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2018[J]. CA:A Cancer Journal for Clinicians, 2018, 68(1):7-30.
[37] Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR[J]. New England Journal of Medicine, 2010, 362(25):2380-2388.